amphetamine has been researched along with Parkinsonian Disorders in 59 studies
Amphetamine: A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE.
1-phenylpropan-2-amine : A primary amine that is isopropylamine in which a hydrogen attached to one of the methyl groups has been replaced by a phenyl group.
amphetamine : A racemate comprising equimolar amounts of (R)-amphetamine (also known as levamphetamine or levoamphetamine) and (S)-amphetamine (also known as dexamfetamine or dextroamphetamine.
Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "L-dopa responsive parkinsonism could be an initial manifestation of Alzheimer's disease, which should be included in the differential diagnosis." | 5.40 | An 85-year old male with levodopa-responsive parkinsonism followed by dementia and supranuclear ophthalmoplegia caused by alzheimer-type pathology without Lewy bodies. ( Hagiwara, M; Kasahata, N; Kato, H; Nakamura, A; Uchihara, T, 2014) |
| "L-dopa responsive parkinsonism could be an initial manifestation of Alzheimer's disease, which should be included in the differential diagnosis." | 1.40 | An 85-year old male with levodopa-responsive parkinsonism followed by dementia and supranuclear ophthalmoplegia caused by alzheimer-type pathology without Lewy bodies. ( Hagiwara, M; Kasahata, N; Kato, H; Nakamura, A; Uchihara, T, 2014) |
| "The severity of the abnormal involuntary movements induced by L-DOPA correlated with the basal firing parameters of LC neuronal activity." | 1.37 | The locus coeruleus is directly implicated in L-DOPA-induced dyskinesia in parkinsonian rats: an electrophysiological and behavioural study. ( Aristieta, A; Cenci, MA; Miguelez, C; Ugedo, L, 2011) |
| " We now show that they are associated with the chronic administration of L-DOPA prior to the transplantation surgery." | 1.35 | Priming for L-DOPA-induced abnormal involuntary movements increases the severity of amphetamine-induced dyskinesia in grafted rats. ( Brundin, P; Cenci, MA; Lane, EL; Vercammen, L, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (5.08) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 28 (47.46) | 29.6817 |
| 2010's | 26 (44.07) | 24.3611 |
| 2020's | 2 (3.39) | 2.80 |
| Authors | Studies |
|---|---|
| Antipova, V | 1 |
| Holzmann, C | 1 |
| Hawlitschka, A | 1 |
| Witt, M | 1 |
| Wree, A | 1 |
| Christensen, AB | 1 |
| Sørensen, JCH | 1 |
| Ettrup, KS | 1 |
| Orlowski, D | 1 |
| Bjarkam, CR | 1 |
| Leino, S | 1 |
| Koski, SK | 1 |
| Hänninen, R | 1 |
| Tapanainen, T | 1 |
| Rannanpää, S | 1 |
| Salminen, O | 1 |
| Cardoso, T | 1 |
| Adler, AF | 1 |
| Mattsson, B | 1 |
| Hoban, DB | 1 |
| Nolbrant, S | 1 |
| Wahlestedt, JN | 1 |
| Kirkeby, A | 1 |
| Grealish, S | 1 |
| Björklund, A | 3 |
| Parmar, M | 1 |
| Qian, Y | 1 |
| Chen, XX | 1 |
| Wang, W | 1 |
| Li, JJ | 1 |
| Wang, XP | 1 |
| Tang, ZW | 1 |
| Xu, JT | 1 |
| Lin, H | 1 |
| Yang, ZY | 1 |
| Li, LY | 1 |
| Song, XB | 1 |
| Guo, JZ | 1 |
| Bian, LG | 1 |
| Zhou, L | 1 |
| Lu, D | 1 |
| Deng, XL | 1 |
| Madathil, SK | 1 |
| Karuppagounder, SS | 1 |
| Mohanakumar, KP | 4 |
| Hubbard, D | 1 |
| Hacksell, U | 1 |
| McFarland, K | 1 |
| Shin, E | 1 |
| Lisci, C | 1 |
| Tronci, E | 2 |
| Fidalgo, C | 1 |
| Stancampiano, R | 1 |
| Carta, M | 2 |
| Kasahata, N | 1 |
| Hagiwara, M | 1 |
| Kato, H | 1 |
| Nakamura, A | 1 |
| Uchihara, T | 1 |
| Effenberg, A | 1 |
| Klein, A | 1 |
| Gibb, R | 1 |
| Carroll, C | 1 |
| Baumgärtner, W | 1 |
| Grothe, C | 1 |
| Ratzka, A | 1 |
| Healy-Stoffel, M | 1 |
| Omar Ahmad, S | 1 |
| Stanford, JA | 1 |
| Levant, B | 1 |
| Tripathy, D | 1 |
| Verma, P | 1 |
| Nthenge-Ngumbau, DN | 1 |
| Banerjee, M | 1 |
| Valle-Leija, P | 1 |
| Drucker-Colín, R | 1 |
| Boix, J | 1 |
| Padel, T | 1 |
| Paul, G | 1 |
| Furlanetti, LL | 1 |
| Coenen, VA | 1 |
| Aranda, IA | 1 |
| Döbrössy, MD | 1 |
| Konieczny, J | 2 |
| Lenda, T | 2 |
| Czarnecka, A | 2 |
| Kamińska, K | 1 |
| Antkiewicz-Michaluk, L | 1 |
| Fjodorova, M | 1 |
| Torres, EM | 1 |
| Dunnett, SB | 2 |
| Hao, F | 1 |
| Yang, C | 1 |
| Chen, SS | 1 |
| Wang, YY | 1 |
| Zhou, W | 1 |
| Hao, Q | 1 |
| Lu, T | 1 |
| Hoffer, B | 1 |
| Zhao, LR | 1 |
| Duan, WM | 1 |
| Xu, QY | 1 |
| Russ, K | 1 |
| Flores, J | 1 |
| Brudek, T | 1 |
| Doudet, DJ | 1 |
| Larramendy, C | 1 |
| Taravini, IR | 1 |
| Saborido, MD | 1 |
| Ferrario, JE | 1 |
| Murer, MG | 1 |
| Gershanik, OS | 1 |
| Guilarte, TR | 1 |
| Burton, NC | 1 |
| McGlothan, JL | 1 |
| Verina, T | 1 |
| Zhou, Y | 1 |
| Alexander, M | 1 |
| Pham, L | 1 |
| Griswold, M | 1 |
| Wong, DF | 1 |
| Syversen, T | 1 |
| Schneider, JS | 1 |
| Lane, EL | 3 |
| Vercammen, L | 1 |
| Cenci, MA | 3 |
| Brundin, P | 2 |
| Glavaski-Joksimovic, A | 1 |
| Virag, T | 1 |
| Chang, QA | 1 |
| West, NC | 1 |
| Mangatu, TA | 1 |
| McGrogan, MP | 1 |
| Dugich-Djordjevic, M | 1 |
| Bohn, MC | 1 |
| Christine, CW | 1 |
| Garwood, ER | 1 |
| Schrock, LE | 1 |
| Austin, DE | 1 |
| McCulloch, CE | 1 |
| Wang, F | 1 |
| Yasuhara, T | 1 |
| Shingo, T | 1 |
| Kameda, M | 1 |
| Tajiri, N | 1 |
| Yuan, WJ | 1 |
| Kondo, A | 1 |
| Kadota, T | 1 |
| Baba, T | 1 |
| Tayra, JT | 1 |
| Kikuchi, Y | 1 |
| Miyoshi, Y | 1 |
| Date, I | 1 |
| Palner, M | 1 |
| Kjaerby, C | 1 |
| Knudsen, GM | 1 |
| Cumming, P | 1 |
| Miguelez, C | 1 |
| Aristieta, A | 1 |
| Ugedo, L | 1 |
| Chao, OY | 1 |
| Mattern, C | 1 |
| Silva, AM | 1 |
| Wessler, J | 1 |
| Ruocco, LA | 1 |
| Nikolaus, S | 1 |
| Huston, JP | 1 |
| Pum, ME | 1 |
| Smith, GA | 1 |
| Kumar, A | 1 |
| Sharma, N | 1 |
| Gupta, A | 1 |
| Kalonia, H | 1 |
| Mishra, J | 1 |
| Bezard, E | 1 |
| Pioli, EY | 1 |
| Li, Q | 1 |
| Porras, G | 1 |
| Xu, R | 1 |
| Hranilovic, D | 1 |
| Fetsko, LA | 1 |
| Bucan, M | 1 |
| Wang, Y | 1 |
| Balcioglu, A | 1 |
| Zhang, K | 1 |
| Tarazi, FI | 1 |
| Kemmerer, ES | 1 |
| Desmond, TJ | 1 |
| Albin, RL | 1 |
| Kilbourn, MR | 1 |
| Frey, KA | 1 |
| SCHWAB, RS | 1 |
| ENGLAND, AC | 1 |
| AUQUIER, L | 1 |
| BONIS, A | 1 |
| HAMBURGER, J | 1 |
| LHERMITTE, F | 1 |
| PEQUIGNOT, H | 1 |
| DESCHAEPDRYVER, A | 1 |
| Chen, JF | 1 |
| Fredduzzi, S | 1 |
| Bastia, E | 1 |
| Yu, L | 1 |
| Moratalla, R | 1 |
| Ongini, E | 1 |
| Schwarzschild, MA | 1 |
| Fernandez-Espejo, E | 1 |
| Caraballo, I | 1 |
| Rodriguez de Fonseca, F | 1 |
| Ferrer, B | 1 |
| El Banoua, F | 1 |
| Flores, JA | 1 |
| Galan-Rodriguez, B | 1 |
| Sortwell, CE | 1 |
| Collier, TJ | 1 |
| Camargo, MD | 1 |
| Pitzer, MR | 1 |
| Marazziti, D | 1 |
| Golini, E | 1 |
| Mandillo, S | 1 |
| Magrelli, A | 1 |
| Witke, W | 1 |
| Matteoni, R | 1 |
| Tocchini-Valentini, GP | 1 |
| Jenkins, BG | 1 |
| Sanchez-Pernaute, R | 1 |
| Brownell, AL | 1 |
| Chen, YC | 1 |
| Isacson, O | 3 |
| Ahmad, M | 1 |
| Saleem, S | 1 |
| Ahmad, AS | 1 |
| Yousuf, S | 1 |
| Ansari, MA | 1 |
| Khan, MB | 1 |
| Ishrat, T | 1 |
| Chaturvedi, RK | 1 |
| Agrawal, AK | 1 |
| Islam, F | 1 |
| Sindhu, KM | 2 |
| Saravanan, KS | 2 |
| Fu, YS | 1 |
| Cheng, YC | 1 |
| Lin, MY | 1 |
| Cheng, H | 1 |
| Chu, PM | 1 |
| Chou, SC | 1 |
| Shih, YH | 1 |
| Ko, MH | 1 |
| Sung, MS | 1 |
| Winkler, C | 1 |
| Senthilkumar, KS | 1 |
| Carlson, KM | 1 |
| Wagner, GC | 1 |
| McCoy, MK | 1 |
| Martinez, TN | 1 |
| Ruhn, KA | 1 |
| Szymkowski, DE | 1 |
| Smith, CG | 1 |
| Botterman, BR | 1 |
| Tansey, KE | 1 |
| Tansey, MG | 1 |
| Fang, X | 1 |
| Sugiyama, K | 1 |
| Akamine, S | 1 |
| Namba, H | 1 |
| Offen, D | 1 |
| Barhum, Y | 1 |
| Levy, YS | 1 |
| Burshtein, A | 1 |
| Panet, H | 1 |
| Cherlow, T | 1 |
| Melamed, E | 1 |
| Hedlund, E | 1 |
| Pruszak, J | 1 |
| Lardaro, T | 1 |
| Ludwig, W | 1 |
| Viñuela, A | 1 |
| Kim, KS | 1 |
| Baker, KA | 1 |
| Sadi, D | 1 |
| Hong, M | 1 |
| Mendez, I | 1 |
| Roghani, M | 1 |
| Behzadi, G | 1 |
| Olds, ME | 1 |
| Jacques, DB | 1 |
| Kopyov, O | 1 |
| Blandini, F | 1 |
| Greenamyre, JT | 1 |
| Fancellu, R | 1 |
| Nappi, G | 1 |
| Crocker, SJ | 1 |
| Wigle, N | 1 |
| Liston, P | 1 |
| Thompson, CS | 1 |
| Lee, CJ | 1 |
| Xu, D | 1 |
| Roy, S | 1 |
| Nicholson, DW | 1 |
| Park, DS | 1 |
| MacKenzie, A | 1 |
| Korneluk, RG | 1 |
| Robertson, GS | 1 |
| Moore, AE | 1 |
| Cicchetti, F | 1 |
| Hennen, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| STEM-PD Trial: A Multicentre, Single Arm, First in Human, Dose-escalation Trial, Investigating the Safety and Tolerability of Intraputamenal Transplantation of Human Embryonic Stem Cell Derived Dopaminergic Cells for Parkinson's Disease (STEM-PD Product)[NCT05635409] | Phase 1 | 8 participants (Anticipated) | Interventional | 2022-11-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for amphetamine and Parkinsonian Disorders
| Article | Year |
|---|---|
[PSYCHOPHARMACA: OBSERVATIONS AND INTERPRETATIONS].
Topics: Amphetamine; Amphetamines; Caudate Nucleus; Central Nervous System Stimulants; Chlorpromazine; Dihyd | 1964 |
58 other studies available for amphetamine and Parkinsonian Disorders
| Article | Year |
|---|---|
Antidepressant-Like Properties of Intrastriatal Botulinum Neurotoxin-A Injection in a Unilateral 6-OHDA Rat Model of Parkinson's Disease.
Topics: Amphetamine; Animals; Antidepressive Agents; Apomorphine; Behavior, Animal; Botulinum Toxins, Type A | 2021 |
Pirouetting pigs: A large non-primate animal model based on unilateral 6-hydroxydopamine lesioning of the nigrostriatal pathway.
Topics: Amphetamine; Animals; Apomorphine; Biophysics; Central Nervous System Stimulants; Corpus Striatum; D | 2018 |
Attenuated dopaminergic neurodegeneration and motor dysfunction in hemiparkinsonian mice lacking the α5 nicotinic acetylcholine receptor subunit.
Topics: Amphetamine; Animals; Antiparkinson Agents; Brain; Central Nervous System Stimulants; Dopamine; Dopa | 2018 |
Target-specific forebrain projections and appropriate synaptic inputs of hESC-derived dopamine neurons grafted to the midbrain of parkinsonian rats.
Topics: Amphetamine; Animals; Dopamine Uptake Inhibitors; Dopaminergic Neurons; Female; Humans; Hydroxydopam | 2018 |
Transplantation of Nurr1-overexpressing neural stem cells and microglia for treating parkinsonian rats.
Topics: Amphetamine; Animals; Behavior, Animal; Calcium-Binding Proteins; Cell Differentiation; Corpus Stria | 2020 |
Sodium salicylate protects against rotenone-induced parkinsonism in rats.
Topics: Amphetamine; Animals; Apomorphine; Corpus Striatum; Cyclooxygenase Inhibitors; Dopamine; Dose-Respon | 2013 |
Behavioral effects of clozapine, pimavanserin, and quetiapine in rodent models of Parkinson's disease and Parkinson's disease psychosis: evaluation of therapeutic ratios.
Topics: Amphetamine; Animals; Antiparkinson Agents; Antipsychotic Agents; Apomorphine; Clozapine; Dopamine; | 2013 |
The anti-dyskinetic effect of dopamine receptor blockade is enhanced in parkinsonian rats following dopamine neuron transplantation.
Topics: Amphetamine; Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Benzazepines; Buspirone; Disease | 2014 |
An 85-year old male with levodopa-responsive parkinsonism followed by dementia and supranuclear ophthalmoplegia caused by alzheimer-type pathology without Lewy bodies.
Topics: Aged, 80 and over; Alzheimer Disease; Amphetamine; Dementia; Humans; Imaging, Three-Dimensional; Lev | 2014 |
Adult hemiparkinsonian rats do not benefit from tactile stimulation.
Topics: Adrenergic Agents; Amphetamine; Animals; Corpus Striatum; Dendrites; Disease Models, Animal; Functio | 2014 |
Differential effects of intrastriatal 6-hydroxydopamine on cell number and morphology in midbrain dopaminergic subregions of the rat.
Topics: Amphetamine; Animals; Cell Count; Cell Nucleolus; Cell Shape; Cell Size; Central Nervous System Stim | 2014 |
Regenerative therapy in experimental parkinsonism: mixed population of differentiated mouse embryonic stem cells, rather than magnetically sorted and enriched dopaminergic cells provide neuroprotection.
Topics: Adrenergic Agents; Amphetamine; Animals; Apomorphine; Brain; Cell Differentiation; Disease Models, A | 2014 |
Unilateral olfactory deficit in a hemiparkinson's disease mouse model.
Topics: Amphetamine; Animals; Central Nervous System Stimulants; Corpus Striatum; Discrimination, Psychologi | 2014 |
A partial lesion model of Parkinson's disease in mice--characterization of a 6-OHDA-induced medial forebrain bundle lesion.
Topics: Amphetamine; Animals; Area Under Curve; Dopamine Agents; Dopaminergic Neurons; Dose-Response Relatio | 2015 |
Chronic deep brain stimulation of the medial forebrain bundle reverses depressive-like behavior in a hemiparkinsonian rodent model.
Topics: Adrenergic Agents; Amphetamine; Animals; Central Nervous System Stimulants; Deep Brain Stimulation; | 2015 |
Early increase in dopamine release in the ipsilateral striatum after unilateral intranigral administration of lactacystin produces spontaneous contralateral rotations in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcysteine; Amphetamine; Animals; Benzazepines; Central Nervous | 2016 |
The significance of rotational behavior and sensitivity of striatal dopamine receptors in hemiparkinsonian rats: A comparative study of lactacystin and 6-OHDA.
Topics: Acetylcysteine; Amphetamine; Animals; Apomorphine; Benzazepines; Central Nervous System Stimulants; | 2017 |
Transplantation site influences the phenotypic differentiation of dopamine neurons in ventral mesencephalic grafts in Parkinsonian rats.
Topics: Adrenergic Agents; Amphetamine; Animals; Brain Tissue Transplantation; Disease Models, Animal; Dopam | 2017 |
Long-term protective effects of AAV9-mesencephalic astrocyte-derived neurotrophic factor gene transfer in parkinsonian rats.
Topics: Adenoviridae; Adrenergic Agents; Amphetamine; Animals; Cells, Cultured; Disease Models, Animal; Dopa | 2017 |
Differential behavioral outcomes following neonatal versus fetal human retinal pigment epithelial cell striatal implants in parkinsonian rats.
Topics: Amphetamine; Animals; Cell Survival; Cell Transplantation; Cellular Senescence; Central Nervous Syst | 2017 |
Cabergoline and pramipexole fail to modify already established dyskinesias in an animal model of parkinsonism.
Topics: Amphetamine; Animals; Antiparkinson Agents; Behavior, Animal; Benzothiazoles; Cabergoline; Disease M | 2008 |
Impairment of nigrostriatal dopamine neurotransmission by manganese is mediated by pre-synaptic mechanism(s): implications to manganese-induced parkinsonism.
Topics: Amphetamine; Animals; Cocaine; Corpus Striatum; Cyclohexanols; Disease Models, Animal; Dopamine; Dop | 2008 |
Priming for L-DOPA-induced abnormal involuntary movements increases the severity of amphetamine-induced dyskinesia in grafted rats.
Topics: Amphetamine; Animals; Antiparkinson Agents; Brain Tissue Transplantation; Central Nervous System Sti | 2009 |
Reversal of dopaminergic degeneration in a parkinsonian rat following micrografting of human bone marrow-derived neural progenitors.
Topics: Amphetamine; Animals; Bone Marrow Cells; Cell Communication; Cell Line; Corpus Striatum; Disease Mod | 2009 |
Parkinsonism in patients with a history of amphetamine exposure.
Topics: Adult; Amphetamine; Amphetamine-Related Disorders; Case-Control Studies; Dopamine Agents; Environmen | 2010 |
Intravenous administration of mesenchymal stem cells exerts therapeutic effects on parkinsonian model of rats: focusing on neuroprotective effects of stromal cell-derived factor-1alpha.
Topics: Amphetamine; Animals; Biomarkers; Chemokine CXCL12; Corpus Striatum; Cytoprotection; Disease Models, | 2010 |
Effects of unilateral 6-OHDA lesions on [3H]-N-propylnorapomorphine binding in striatum ex vivo and vulnerability to amphetamine-evoked dopamine release in rat.
Topics: Amphetamine; Animals; Apomorphine; Binding, Competitive; Corpus Striatum; Disease Models, Animal; Do | 2011 |
The locus coeruleus is directly implicated in L-DOPA-induced dyskinesia in parkinsonian rats: an electrophysiological and behavioural study.
Topics: Amphetamine; Animals; Behavior, Animal; Dyskinesias; Electrophysiology; Female; Ibotenic Acid; Levod | 2011 |
Intranasally applied L-DOPA alleviates parkinsonian symptoms in rats with unilateral nigro-striatal 6-OHDA lesions.
Topics: 3,4-Dihydroxyphenylacetic Acid; Administration, Intranasal; Amphetamine; Analysis of Variance; Anima | 2012 |
Amphetamine-induced rotation in the transplanted hemi-parkinsonian rat--response to pharmacological modulation.
Topics: Amphetamine; Animals; Brain Tissue Transplantation; Disease Models, Animal; Dopamine Agents; Dopamin | 2012 |
Neuroprotective potential of atorvastatin and simvastatin (HMG-CoA reductase inhibitors) against 6-hydroxydopamine (6-OHDA) induced Parkinson-like symptoms.
Topics: Amphetamine; Analysis of Variance; Animals; Atorvastatin; Corpus Striatum; Disease Models, Animal; D | 2012 |
Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia.
Topics: Amantadine; Amphetamine; Animals; Apomorphine; Disease Models, Animal; Dopamine Agents; Dyskinesia, | 2013 |
Dopamine D2S and D2L receptors may differentially contribute to the actions of antipsychotic and psychotic agents in mice.
Topics: Amphetamine; Animals; Antipsychotic Agents; Apomorphine; Clozapine; Dopamine Agonists; Dose-Response | 2002 |
Dopamine depletion abolishes apomorphine- and amphetamine-induced increases in extracellular serotonin levels in the striatum of conscious rats: a microdialysis study.
Topics: Afferent Pathways; Amphetamine; Animals; Apomorphine; Binding, Competitive; Carrier Proteins; Denerv | 2003 |
Treatment effects on nigrostriatal projection integrity in partial 6-OHDA lesions: comparison of L-DOPA and pramipexole.
Topics: Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Autoradiography; Behavior, Animal; Benzothi | 2003 |
Problems in the treatment of Parkinsonism by analeptics.
Topics: Amphetamine; Amphetamines; Apomorphine; Central Nervous System Stimulants; Humans; Parkinson Disease | 1956 |
[PRESENT STATUS OF THE TREATMENT OF PARKINSON'S DISEASE].
Topics: Alkaloids; Amphetamine; Histamine H1 Antagonists; Neurosurgery; Neurosurgical Procedures; Parkinson | 1964 |
Adenosine A2A receptors in neuroadaptation to repeated dopaminergic stimulation: implications for the treatment of dyskinesias in Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; Amphetamine; Animals; Antiparkinson Agents; Behavior, Animal; Dis | 2003 |
Experimental parkinsonism alters anandamide precursor synthesis, and functional deficits are improved by AM404: a modulator of endocannabinoid function.
Topics: Acyltransferases; Amidohydrolases; Amphetamine; Analysis of Variance; Animals; Antiparkinson Agents; | 2004 |
An in vitro interval before transplantation of mesencephalic reaggregates does not compromise survival or functionality.
Topics: Amphetamine; Animals; Brain Tissue Transplantation; Cell Count; Cell Survival; Cells, Cultured; Dise | 2004 |
Altered dopamine signaling and MPTP resistance in mice lacking the Parkinson's disease-associated GPR37/parkin-associated endothelin-like receptor.
Topics: Amphetamine; Animals; Corpus Striatum; Dopamine; Female; Male; Mice; Mice, Inbred C57BL; Motor Activ | 2004 |
Mapping dopamine function in primates using pharmacologic magnetic resonance imaging.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amphetamine; Animals; Brain; Brain Mapping; Cerebrovas | 2004 |
Ginkgo biloba affords dose-dependent protection against 6-hydroxydopamine-induced parkinsonism in rats: neurobehavioural, neurochemical and immunohistochemical evidences.
Topics: Amphetamine; Animals; Apomorphine; Behavior, Animal; Brain Chemistry; Catecholamines; Disease Models | 2005 |
Behavioral differences in a rotenone-induced hemiparkinsonian rat model developed following intranigral or median forebrain bundle infusion.
Topics: Adrenergic Agents; Amphetamine; Animals; Dopamine; Electron Transport Complex I; Enzyme Inhibitors; | 2005 |
Conversion of human umbilical cord mesenchymal stem cells in Wharton's jelly to dopaminergic neurons in vitro: potential therapeutic application for Parkinsonism.
Topics: Amphetamine; Animals; Brain; Cell Differentiation; Cord Blood Stem Cell Transplantation; Culture Med | 2006 |
The impact of graft size on the development of dyskinesia following intrastriatal grafting of embryonic dopamine neurons in the rat.
Topics: Amphetamine; Animals; Brain Tissue Transplantation; Corpus Striatum; Disease Models, Animal; Dopamin | 2006 |
L-deprenyl protects against rotenone-induced, oxidative stress-mediated dopaminergic neurodegeneration in rats.
Topics: Amphetamine; Animals; Catalase; Disease Models, Animal; Dopamine; Dopamine Agents; Dose-Response Rel | 2006 |
Voluntary exercise and tail shock have differential effects on amphetamine-induced dopaminergic toxicity in adult BALB/c mice.
Topics: Amphetamine; Animals; Cell Survival; Corpus Striatum; Corticosterone; Dopamine; Drinking; Eating; El | 2006 |
Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease.
Topics: Amphetamine; Animals; Cell Death; Cells, Cultured; Coculture Techniques; Disease Models, Animal; Dop | 2006 |
Improvements in motor behavioral tests during deep brain stimulation of the subthalamic nucleus in rats with different degrees of unilateral parkinsonism.
Topics: Amphetamine; Analysis of Variance; Animals; Behavior, Animal; Central Nervous System Stimulants; Dee | 2006 |
Intrastriatal transplantation of mouse bone marrow-derived stem cells improves motor behavior in a mouse model of Parkinson's disease.
Topics: Amphetamine; Animals; Blotting, Western; Bone Marrow Transplantation; Cell Differentiation; Cell Mov | 2007 |
Embryonic stem cell-derived Pitx3-enhanced green fluorescent protein midbrain dopamine neurons survive enrichment by fluorescence-activated cell sorting and function in an animal model of Parkinson's disease.
Topics: Amphetamine; Animals; Apomorphine; Cell Differentiation; Cell Survival; Embryonic Stem Cells; Flow C | 2008 |
Simultaneous intrastriatal and intranigral dopaminergic grafts in the parkinsonian rat model: role of the intranigral graft.
Topics: Amphetamine; Animals; Brain Tissue Transplantation; Denervation; Disease Models, Animal; Dopamine; F | 2000 |
Neuroprotective effect of vitamin E on the early model of Parkinson's disease in rat: behavioral and histochemical evidence.
Topics: Amphetamine; Animals; Apomorphine; Atrophy; Axonal Transport; Corpus Striatum; Disease Models, Anima | 2001 |
Entopeduncular lesions facilitate and thalamic lesions depress spontaneous and drug-evoked motor behavior in the hemiparkinsonian rat.
Topics: Amphetamine; Animals; Apomorphine; Denervation; Disease Models, Animal; Dopamine Agonists; Dyskinesi | 2001 |
Blockade of subthalamic glutamatergic activity corrects changes in neuronal metabolism and motor behavior in rats with nigrostriatal lesions.
Topics: Amphetamine; Animals; Dizocilpine Maleate; Energy Metabolism; Excitatory Amino Acid Antagonists; Fun | 2001 |
NAIP protects the nigrostriatal dopamine pathway in an intrastriatal 6-OHDA rat model of Parkinson's disease.
Topics: Amphetamine; Amyloid beta-Protein Precursor; Animals; Antibodies; Caspase 3; Caspases; Cell Survival | 2001 |
Parkinsonian motor deficits are reflected by proportional A9/A10 dopamine neuron degeneration in the rat.
Topics: Amphetamine; Animals; Apomorphine; Behavior, Animal; Dopamine; Dopamine Agents; Dopamine Agonists; E | 2001 |